Sangamo Therapeutics Stock Current Valuation
| SGMO Stock | USD 0.51 0.02 4.08% |
Valuation analysis of Sangamo Therapeutics helps investors to measure Sangamo Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 23rd of April 2024, Enterprise Value Over EBITDA is likely to drop to -1. In addition to that, Enterprise Value Multiple is likely to drop to -1. Fundamental drivers impacting Sangamo Therapeutics' valuation include:
Price Book 1.3519 | Enterprise Value 48.6 M | Enterprise Value Ebitda (0.71) | Price Sales 0.628 | Enterprise Value Revenue 0.3924 |
Undervalued
Today
Please note that Sangamo Therapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Sangamo Therapeutics is based on 3 months time horizon. Increasing Sangamo Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Sangamo Therapeutics is useful when determining the fair value of the Sangamo stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Sangamo Therapeutics. Since Sangamo Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sangamo Stock. However, Sangamo Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.51 | Real 2.02 | Target 6.58 | Hype 0.46 |
The real value of Sangamo Stock, also known as its intrinsic value, is the underlying worth of Sangamo Therapeutics Company, which is reflected in its stock price. It is based on Sangamo Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Sangamo Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sangamo Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sangamo Therapeutics helps investors to forecast how Sangamo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sangamo Therapeutics more accurately as focusing exclusively on Sangamo Therapeutics' fundamentals will not take into account other important factors: Sangamo Therapeutics Company Current Valuation Analysis
Sangamo Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sangamo Therapeutics Current Valuation | 48.61 M |
Most of Sangamo Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sangamo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sangamo Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Sangamo Therapeutics is extremely important. It helps to project a fair market value of Sangamo Stock properly, considering its historical fundamentals such as Current Valuation. Since Sangamo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sangamo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sangamo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Sangamo Current Valuation Historical Pattern
Today, most investors in Sangamo Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sangamo Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sangamo Therapeutics current valuation as a starting point in their analysis.
Sangamo Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sangamo Therapeutics has a Current Valuation of 48.61 M. This is 99.66% lower than that of the Biotechnology sector and 98.95% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.71% higher than that of the company.
Sangamo Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sangamo Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sangamo Therapeutics could also be used in its relative valuation, which is a method of valuing Sangamo Therapeutics by comparing valuation metrics of similar companies.Sangamo Therapeutics is currently under evaluation in current valuation category among related companies.
Sangamo Fundamentals
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (1.46) % | ||||
| Operating Margin | (24.76) % | ||||
| Current Valuation | 48.61 M | ||||
| Shares Outstanding | 203.67 M | ||||
| Shares Owned By Insiders | 9.40 % | ||||
| Shares Owned By Institutions | 47.59 % | ||||
| Number Of Shares Shorted | 11.41 M | ||||
| Price To Earning | (15.31) X | ||||
| Price To Book | 1.35 X | ||||
| Price To Sales | 0.63 X | ||||
| Revenue | 176.23 M | ||||
| Gross Profit | (138.6 M) | ||||
| EBITDA | (92.1 M) | ||||
| Net Income | (257.83 M) | ||||
| Cash And Equivalents | 315.72 M | ||||
| Cash Per Share | 2.02 X | ||||
| Total Debt | 38.1 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 2.86 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (224.84 M) | ||||
| Short Ratio | 5.05 X | ||||
| Earnings Per Share | (1.48) X | ||||
| Target Price | 3.5 | ||||
| Number Of Employees | 405 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 104.18 M | ||||
| Total Asset | 165.32 M | ||||
| Retained Earnings | (1.41 B) | ||||
| Working Capital | 46.6 M | ||||
| Current Asset | 212.58 M | ||||
| Current Liabilities | 20.1 M | ||||
| Net Asset | 165.32 M |
About Sangamo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sangamo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sangamo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sangamo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:Check out Sangamo Therapeutics Piotroski F Score and Sangamo Therapeutics Altman Z Score analysis. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Sangamo Stock analysis
When running Sangamo Therapeutics' price analysis, check to measure Sangamo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangamo Therapeutics is operating at the current time. Most of Sangamo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sangamo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangamo Therapeutics' price. Additionally, you may evaluate how the addition of Sangamo Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 1.01 | Quarterly Revenue Growth (0.93) | Return On Assets (0.18) | Return On Equity (1.36) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.